Navigation Links
WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
Date:12/2/2008

ations.

Other relevant factors include: uncertainty in the global economy may adversely impact our business and the trends for outsourced R&D and manufacturing; pharmaceutical and biotechnology companies may not change their business models as expected or in a manner favorable to us; we may fail to capitalize on the opportunities presented; we may not maintain our preferred provider status with our clients; and may be unable to expand our capabilities successfully to meet client needs. In addition other factors that could cause our actual results to differ from what we currently anticipate include: our limited operating history; failure to generate sufficient future cash flows or secure any required future financing on acceptable terms or at all; failure to retain key personnel; effective integration of products and services from AppTec; our reliance on a limited number of customers to continue to account for a high percentage of our revenues; risk of payment failure by any of our large customers, which could significantly harm our cash flows and profitability; dependency upon the continued service of our senior management and key scientific personnel and ability to retain our existing customers or expand our customer base. The financial information contained in this release should be read in conjunction with the consolidated and pro forma financial statements and notes thereto included in our 2007 Annual Report on Form 20-F filed with available on the Securities and Exchange Commission's website at http://www.sec.gov . For additional information on these and other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on Page 10 of our 2007 Annual Report on Form 20-F. Any projections in this release are based on limited information currently available to us, which is subject to chan
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
2. WuXi PharmaTech Announces Second Quarter 2007 Results
3. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
4. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
5. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
6. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
7. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
8. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
9. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
10. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
11. WuXi PharmaTech Completes Acquisition of AppTec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 Whitehouse Laboratories has formally announced ... Testing and Package Test Capacity. Responding to growing demands ... dramatic increase in environmental chamber storage space that will ... aging samples to be securely held on site at ... expenditure has already taken place with the recent completion ...
(Date:10/30/2014)... Calif. , Oct. 30, 2014 Isis Pharmaceuticals, ... therapeutics, today announced that management will present a company overview ... at 8:30 a.m. ET in Boston, MA. ... be available on the "Investors & Media" section of the ... on the Isis website within 48 hours and will be ...
(Date:10/30/2014)... challenges in the development of quantum technologies has been ... paper published today (28 October) in Nature Communications ... make a new type of flexibly designed microscopic trap ... sensors and specialised superfast computers, often depend on harnessing ... trapping these tiny particles are hugely problematic because of ...
(Date:10/27/2014)... The new research report, “Gas Insulated Switchgear (GIS) ... & Secondary), and End-User (Transmission & Distribution, Manufacturing ... - Trends and Forecasts to 2019”, defines and ... of the market size. , Browse more than ... through 146 Pages and in-depth TOC on “Gas ...
Breaking Biology Technology:Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
... Oct. 10 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; Nasdaq: PXSL) ... a placement to Australian, U.S., Asian and European ... balance,sheet as Pharmaxis continues with a series of ... of its manufacturing operation in,Sydney. Pharmaxis will ...
... October 10 The National,Institutes of Allergy and ... with Bavarian Nordic to include the initiation of,a ... investigational,smallpox vaccine, in persons diagnosed with atopic dermatitis. ... 2010 and has a value of,US$15 million, with ...
... OPK ),today announced that it has acquired exclusive ... compound with potential utility,in the treatment of dry eye. ... can disrupt the lives,of those afflicted. It can cause ... Sam Reich, Executive Vice President,of Ophthalmologics at OPKO. "There ...
Cached Biology Technology:Pharmaxis Announces Placement of $50 Million and Share Purchase Plan 2Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema 2Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema 3OPKO Health Acquires Rights to Clinical Stage Compound for Dry Eye 2OPKO Health Acquires Rights to Clinical Stage Compound for Dry Eye 3
(Date:10/30/2014)... 30 October 2014 Biological membranes are mainly composed ... adsorption of solution ions onto lipid membranes helps ... new study provides a quantitative description of the ... Joanna Kotyńska and Zbigniew Figaszewski from the University ... study describing these findings, just published in ...
(Date:10/29/2014)... OR) New research presented at the Society ... Houston, TX showed for the first time that ... women using a readily available nutritional supplement, AHCC. ... Dr. Judith A. Smith, Pharm.D., associate professor in ... at The University of Texas Health Science Center ...
(Date:10/29/2014)... the safety of nanoparticles is all the rage. Thousands ... examining the question of whether titanium dioxide nanoparticles from ... the body, whether carbon nanotubes from electronic products are ... be or whether nanoparticles in food can get into ... interest is great, research funds are flowing – and ...
Breaking Biology News(10 mins):Ion adsorption matter in biology 2HPV infections in women eradicated by AHCC, Japanese mushroom extract 2Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3
... Scientists and engineers must join together in a major new ... crisis in providing Earth,s people with clean water that looms ... comment article in the current edition of Chemical & ... Society (ACS), the world,s largest scientific society. Bassam Z. ...
... of potential environmental and human health effects from disposal ... led scientists to recommend stronger government policies to encourage ... That,s the conclusion of a new paper in the ... Oladele A. Ogunseitan and colleagues point out that Li-ion ...
... life scientists provide important new details on how climate change ... 21 in the Journal of Animal Ecology . This ... informing policymakers of how species are likely to be impacted ... recognition among biologists that climate change is affecting how species ...
Cached Biology News:UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5
... BioNumerics is the universal bioinformatics software that ... data. The unique modular design of BioNumerics ... virtually any type of data employed for ... microarrays, DNA fingerprints, 2-D protein gels, HPLC, ...
... early 80s Biosearch Technologies has been ... tools to accelerate the discovery and ... need dual-labeled FRET probes and primers ... for microarray applications, Biosearch can meet ...
UNIVERSAL SCORECARD DNA, 1 EA. * Category: Reagents/Consumables....
mitochondrial proteins (human heart) for 2-D gel electrophoresis *5 mg/mL*...
Biology Products: